Medtronic Affera™ Mapping and Ablation System with Sphere-9™ Catheter achieves endpoints for safety and efficacy, providing promising evidence for the future of atrial fibrillation treatment
HRS late breaking data: SPHERE Per-AF trial demonstrates novel all-in-one system delivers exceptional results, plus increased efficiency and improved quality of life DUBLIN and BOSTON, May 18, 2024 /PRNewswire/ — Medtronic plc , a global leader in healthcare technology, today announced positive results demonstrating excellent safety and efficacy of the Affera™ Mapping